NVO250110C91000
- 0.01
- 0.000.00%
Novo-Nordisk A/S Newsroom
Allurion (ALUR.US) stock price surged violently; its new weight loss therapy can maintain muscle mass.
On Thursday, Allurion's stock price soared 80% in after-hours trading, following reports that the company plans to conduct clinical research combining its gastric balloon weight loss product with GLP-1 drugs.
Allurion Stock Soars 70% on Weight-loss Therapy Update
Top Gap Ups and Downs on Thursday: GE, ASML, MU and More
Fund Update: Mediolanum International Funds Ltd Just Disclosed New Holdings
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com
Sales are disappointing, and the market scale is questionable....... The trade of overseas weight-loss drug stocks is cooling down.
Due to disappointing clinical trial results for new drugs and sales data below expectations for two consecutive quarters, the stock prices of Novo-Nordisk A/S and Eli Lilly and Co have fallen from their historical highs. Novo-Nordisk A/S has missed out on the top spot in the European stock market, and stocks related to weight loss drugs have entered bear market territory.
Novo Nordisk Very Interested in Small Nuclear Reactors, Chairman Says -- Market Talk
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention Therapeutix Enters Collaboration With Novo Nordisk for Sickle Cell Disease Therapies
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Novo Nordisk to Further Scale Up Production, Supply, Employment -- Market Talk
Moody's upgraded Novo-Nordisk A/S's credit rating to Aa3, with a "positive" outlook.
The credit rating agency Moody's has upgraded the long-term credit rating of Danish pharmaceutical giant Novo-Nordisk A/S from A1 to Aa3, with the outlook raised from "stable" to "positive." Moody's stated that this rating upgrade reflects the company's growth in diabetes and obesity medications (mainly Ozempic and Wegovy), as well as a moderate patent risk over the next three years, and a solid and increasingly diversified product line, despite the focus on diabetes and obesity treatment. The institution added that Novo-Nordisk A/S's very strong crediting indicators also played a role. The outlook upgrade is due to Moody's expectation that Novo-Nordisk A/S will continue its growth in the next 12 to 18 months.
Top Gap Ups and Downs on Tuesday: TEM, MMM, DJT and More
GLP-1 Weight Loss Drugs Linked to a Wide Range of Health Benefits and Risks: Study
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
CFRA Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $90
Research: Weight loss drugs can also reduce the risk of Alzheimer's.
Recently, a large-scale study on popular weight loss drugs showed that patients using GLP-1 medications (such as Novo-Nordisk A/S's Ozempic and Wegovy, and Eli Lilly and Co's Mounjaro) had a 12% reduced risk of developing Alzheimer's disease, but there was an increase in the risk of arthritis, kidney, and pancreatic diseases.
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
LVMH Is Once Again the Largest Company in Europe by Market Cap